Sign in Create account
Sign in and upgrade to a paid plan to export futures history as CSV.
Sign in and upgrade to a paid plan to export price history as CSV.

Titan Bio-Tech Ltd.

Chemicals · Chemicals & Petrochemicals

BSE: 524717
₹393.75
▲ 2.95 (0.75%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
76/100
Strong
Valuation
34/100
Fairly Valued
Momentum
47/100
Neutral

QVM read Quality business Quality Strong, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹1,627 Cr
PE (TTM)
18.1
Industry median 24.4 (189 companies)
Price to Book
9.0
PEG (TTM)
-4.2
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-45.9
Free Cash Flow
₹21 Cr
as of March 31, 2026
Industry median ₹-0 Cr (238 companies)
EPS Growth (YoY)
-69.30%
as of June 30, 2026
Industry median 39.08% (220 companies)
Net Profit Growth (TTM)
48.75%
as of June 30, 2026
Industry median 13.45% (212 companies)
Operating Revenue Growth (TTM)
36.93%
as of June 30, 2026
Industry median 7.93% (209 companies)
Profit Growth (YoY)
53.48%
as of June 30, 2026
Industry median 23.11% (213 companies)
Revenue Growth (YoY)
27.25%
as of June 30, 2026
Industry median 17.49% (205 companies)
Current Ratio
3.28
as of March 31, 2026
Industry median 1.87 (237 companies)
Debt to Equity
0.02
as of March 31, 2026
Industry median 0.16 (224 companies)
Interest Coverage
47.65
as of June 30, 2026
Industry median 8.97 (221 companies)
Net Margin
15.98%
as of June 30, 2026
Industry median 7.49% (212 companies)
Operating Margin (EBIT)
21.86%
as of June 30, 2026
Industry median 11.88% (214 companies)
Operating Margin (TTM)
19.97%
as of June 30, 2026
Industry median 9.75% (219 companies)
Return on Assets
13.51%
as of March 31, 2026
Industry median 4.33% (217 companies)
Return on Capital Employed
22.06%
as of March 31, 2026
Industry median 10.34% (218 companies)
Return on Equity
16.07%
as of March 31, 2026
Industry median 7.52% (219 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 6 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.02)
  • Yes Return on equity is 15% or more (16.1%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.8%
Low 380.5000 · High 399.0000
1W return
-1.1%
Low 378.8000 · High 401.0000
1M return
4.6%
Low 378.8000 · High 443.0000
52W return
-48.0%
Low 367.0000 · High 443.0000
Lifetime High ₹757.7500 (Dec. 24, 2024)
Lifetime Low ₹10.1800 (Nov. 3, 2008)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
394.1
10D
398.4
20D
405.8
50D
436.6
100D
461.2
200D
478.9

Delivery and volume

Day avg. delivery
53.0%
Week avg. delivery
62.1%
Month avg. delivery
88.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

391.08
Pivot
First resistance401.67
Second resistance409.58
Third resistance420.17
First support383.17
Second support372.58
Third support364.67
Day RSI42.3
Day MFI58.9
Day MACD-11.91
Day MACD signal-12.67

Beta

1M0.62
3M0.46
1Y0.46
3Y0.75

Price change analysis

↑ 4.6%
Over 1 Month
LowHigh
378.80443.00
↓ -48.0%
Over 3 Months
LowHigh
367.00443.00
↓ -48.0%
Over 6 Months
LowHigh
367.00443.00
↓ -48.0%
Over 1 Year
LowHigh
367.00443.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 18.1 (own history: 18.4–34.9)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹59 Cr
Net profit (June 30, 2026)
₹9 Cr
Basic EPS (June 30, 2026)
₹2.2900

Ranks #68 of 221 in Chemicals & Petrochemicals by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter55.78%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 55.78% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 22 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
4 Aug 2023 ANKITGOYAL Bulk Buy 47,050 307.6100 BSE
23 Apr 2021 NIRAJ RAJNIKANT SHAH Bulk Buy 50,000 277.0800 BSE
1 Dec 2020 AVB SHARES TRADING PRIVATE LIMITED Bulk Sell 47,550 126.8200 BSE
23 Oct 2020 ALPHA LEON ENTERPRISES LLP Bulk Sell 83,992 153.3400 BSE
23 Oct 2020 ALPHA LEON ENTERPRISES LLP Bulk Buy 119,741 152.5500 BSE
24 Aug 2020 BYNASONS Bulk Sell 54,000 194.0000 BSE
14 Aug 2020 WHITE DIAMAND ENTERPRISES PRIVATE LIMITED Bulk Sell 50,000 144.9000 BSE
10 Jun 2020 ZEESHAN ALI MERCHANT Bulk Buy 70,421 71.4700 BSE
10 Jun 2020 ZEESHAN ALI MERCHANT Bulk Sell 70,769 69.5000 BSE
6 Aug 2019 TITAN SECURITIES LTD Bulk Buy 57,750 35.4400 BSE

All bulk and block deals →

Corporate Announcements

All 12 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 Company Update Titan Biotech Ltd - 524717 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
30 Sep 2026 AGM/EGM Titan Biotech Ltd - 524717 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Sep 2026 AGM/EGM Titan Biotech Ltd - 524717 - Shareholder Meeting / Postal Ballot-Outcome of AGM
10 Sep 2026 Company Update Titan Biotech Ltd - 524717 - Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Sep 2026 Company Update Titan Biotech Ltd - 524717 - Announcement under Regulation 30 (LODR)-Newspaper Publication
5 Sep 2026 AGM/EGM Titan Biotech Ltd - 524717 - Notice Of Thirty- Fourth (34Th) Annual General Meeting
5 Sep 2026 Company Update Titan Biotech Ltd - 524717 - Intimation Regarding Weblink To Access The Annual Report For FY 2025-26 And Notice Of The 34Th Annual General Meeting For Shareholders Whose Email Ids Are Not Registered
5 Sep 2026 Others Titan Biotech Ltd - 524717 - Reg. 34 (1) Annual Report.
3 Sep 2026 Board Meeting Titan Biotech Ltd - 524717 - Board Meeting Outcome for Outcome Of Board Meeting Dated September 3, 2026
3 Sep 2026 Corp. Action Titan Biotech Ltd - 524717 - Intimation Of Record Date For The Purpose Of Final Dividend

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.02)
  • Comfortable interest coverage (47.6x)
  • Strong revenue growth YoY (27.3%)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • Down 48.0% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Titan Bio-Tech Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.